false
0000883975
0000883975
2026-11-16
2026-11-16
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 16, 2026
MICROBOT
MEDICAL INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
000-19871 |
|
94-3078125 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
175
Derby St., Bld. 27
Hingham,
MA 02043
(Address
of Principal Executive Offices) (Zip Code)
Registrant’s
telephone number, including area code: (781) 875-3605
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.01 par value |
|
MBOT |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
Growth Company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure.
On
November 16, 2026, Microbot Medical Inc. (the “Company”) disseminated a press release announcing that it has filed its Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30, 2026, and providing highlights of the Company’s third quarter ended
September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The
information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities
of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange
Act, regardless of any general incorporation language in such filing. By furnishing the information in this Current Report on Form 8-K
and Exhibit 99.1, the Company is making no admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit
Number |
|
Description |
| |
|
|
| 99.1 |
|
Press Release dated November 16, 2026 |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
| |
MICROBOT
MEDICAL INC. |
| |
|
| |
By: |
/s/
Harel Gadot |
| |
Name: |
Harel
Gadot |
| |
Title: |
Chief
Executive Officer, President and Chairman |
Date:
November 16, 2026
Exhibit
99.1

Microbot
Medical® Files 10-Q and Highlights Key Third Quarter Operating Achievements
Company
continues to expand commercial presence in the U.S. while it progresses international market entry and opportunities
Increased
the number of health systems and hospital sites using LIBERTY, while utilization of the LIBERTY System rose 44% compared to the second
quarter
HINGHAM,
Mass., November 16, 2026 — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular
Robotic System, today announced that it has filed its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2026, with
the Securities and Exchange Commission.
The
Company reported revenue of $72,000, a sequential decrease compared to revenue of $241,000 during the second quarter ended June 30, 2026.
The revenue decrease in Q3 was due to a number of variables including timing of customer re-orders and the seasonality of Q3 (lower activity
during summer months). In addition, taking into consideration that the Full Market Release commenced approximately 6 months ago, and
that a hospital’s Value Analysis Committee (or “VAC”) process takes approximately 4-6 months, multiple potential new
accounts are still in their VAC process. The Company believes that gaining widespread access to hospital systems through a VAC process
could accelerate adoption of the LIBERTY System across healthcare systems with multiple hospitals over time.
The
Company reports that 100% of current customers who exhausted their initial inventory have reordered multiple systems, reflecting high
customer satisfaction consistent with a Company conducted survey.
During
the third quarter, the Company experienced increased procedure utilization within existing accounts.
As
anticipated, the Company reported a negative gross margin in the third quarter. Cost of goods sold increased by 24% from the second quarter,
largely due to an inventory write-down recognized as a result of measuring inventory at the lower of cost and net realizable value. In
addition, under the Company’s first-in, first-out (FIFO) inventory method, the cost of systems sold during the quarter primarily
reflected units manufactured in earlier periods at higher production costs. While these factors adversely affected gross margin in the
third quarter, the manufacturing cost per unit of systems produced during the quarter continued to decline compared to the previous quarters,
reflecting improvements in manufacturing efficiency. The Company expects its ongoing cost reduction initiatives and the planned addition
of a second manufacturing line, if completed as planned, to further reduce manufacturing costs and believes these measures could enable
it to achieve a positive gross margin during 2027.
Other
Third Quarter and Recent Highlights
| |
● |
The Company ended the third quarter with cash, cash equivalents
and marketable securities of approximately $62 million, enabling the Company to continue executing its commercial strategy in the U.S.
and internationally. |
| |
● |
Utilization (number of procedures) of the LIBERTY Endovascular
Robotic System in Q3 is up 44% compared to Q2. |
| |
● |
Academic center in North Carolina adopted the LIBERTY System,
becoming the Company’s second health system in the state of North Carolina to use the system. |
| |
● |
The Company’s first West Coast customer, located in California,
is also its first Office-Based Lab customer. |
| |
● |
The Company ended the third quarter with 12 customer accounts,
compared to 10 customer accounts at the end of the second quarter. Additionally, the Company added two sales territories during the third
quarter, expanding to ten, and plans to increase to 12 sales territories by the end of 2026. |
| |
● |
Customers have used LIBERTY in a variety of procedure types,
including Prostatic Artery Embolization (PAE), Y-90 Radioembolization, Genicular Artery Embolization (GAE) and Uterine Artery Embolization
(UAE), which the Company believes supports its positioning of the LIBERTY System as a platform for multiple peripheral intervention procedures. |
| |
● |
Following regulatory approval from the Israeli Ministry of
Health’s AMAR Division, the Company entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market
and sell the LIBERTY System in Israel. The Company currently expects to receive initial orders under the agreement during the fourth
quarter of 2026. |
| |
● |
During and after the third quarter, the Company received new
patents in the U.S., Japan, China and Canada. As of this press release, the Company held 44 issued patents and 49 pending patent applications. |
| |
● |
The Company successfully completed the ISO certificate surveillance
audit. |
“In
less than six months since the full market release of the LIBERTY System, we are encouraged by the quality of customers we have added,
and we believe their repeat purchases reflect their satisfaction with LIBERTY,” commented Harel Gadot, CEO, President and Chairman.
“While revenue this quarter in part reflected the seasonality of the third quarter and the sales cycle process associated with
the VAC, we believe the progress we made this year positions us for several potential milestones over the coming months in the U.S. and
the international markets in which we operate.”
LIBERTY
is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, and it is designed for
precise vascular navigation while aiming to reduce radiation exposure and physical strain.
About
Microbot Medical
Microbot
Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced
robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the first single-use, remotely operated robotic solution
designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot
is driving the future of endovascular care.
Learn
more at www.microbotmedical.com and connect on LinkedIn and X.
Safe
Harbor
Statements
relating to future financial and/or operating results, revenue, gross margin, cost reductions, manufacturing capacity, sales territory
expansion, customer orders and re-orders, distributor orders, future adoption of products, future growth in research, technology, clinical
development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements
about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical
fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,”
“forecasts,” “intends,” “may,” “might,” “possible,” “potential,”
“predicts,” “projects,” “should,” “would,” “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be
considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking
statements involve risks and uncertainties that could cause actual results to differ materially, including, without limitation, market
conditions; risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, including the Company’s
limited commercial history and revenue; the length and outcome of hospital Value Analysis Committee and other purchasing processes and
the resulting variability in quarterly revenue; the Company’s ability to retain customers and obtain re-orders; the Company’s
ability to reduce costs, complete its second manufacturing line and achieve positive gross margin; the Company’s ability to hire
and retain sales personnel; the performance of distributors; competition; reimbursement and hospital capital budgets; the Company’s
need for additional capital and its cash resources; risks in the development of future versions of or applications for the system; uncertainty
in the results of regulatory pathways and regulatory approvals; uncertainty resulting from political, social and geopolitical conditions;
disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries; and
maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under
the heading “Risk Factors” in Microbot Medical’s Annual Report on Form 10-K for the year ended December 31, 2025, its
Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 and other periodic reports filed with the Securities and Exchange
Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Forward-looking statements speak only as of the date
of this press release, and readers are cautioned not to place undue reliance on them https://url.us.m.mimecastprotect.com/s/upukC9r3JzIm0GkQSEhvhqNQht?domain=sec.gov.
Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by
law.
Contacts:
IR@microbotmedical.com
Media@microbotmedical.com